Eli Lilly & Co. LLY, +1.23% reported Friday a big fourth-quarter profit beat and revenue that rose 22% to top forecasts, as it recognized $850 million in U.S. revenue for bamlanivimab, the drugmaker's treatment for mile to moderate COVID-19 that has been granted Emergency Use Authorization. The company said it has delivered 950,000 bamlanivimab doses to the U.S. government, and has agreed to deliver 500,000 more doses no later than March 31. The stock was slipped 0.1% in premarket trading. Net income rose to $2.12 billion, or $2.32 a share, from $1.50 billion, or $1.64 a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share grew to $2.75 from $1.73 to beat the FactSet consensus of $2.37. Revenue grew 22% to $7.44 billion, above the FactSet consensus of $7.27 billion, as a 24% increase in volume helped offset a 4% decline in realized prices. For 2021, the company affirmed its adjusted EPS guidance range of $7.75 to $8.40 and its revenue outlook of $26.5 billion to $28.0 billion. The stock has soared 58.5% over the past three months through Thursday, while the S&P 500 SPX, +0.98% has gained 14.4%.